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The interaction of hyaluronan (HA) with mesenchymal progenitor cells impacts trafficking
and fate after tissue colonization during wound repair and these events contribute to
diseases such as cancer. How this interaction occurs is poorly understood. Using 10T½
cells as a mesenchymal progenitor model and fluorescent (F-HA) or gold-labeled HA
(G-HA) polymers, we studied the role of two HA receptors, RHAMM and CD44, in HA
binding and uptake in non-adherent and adherent mesenchymal progenitor (10T½) cells
to mimic aspects of cell trafficking and tissue colonization. We show that fluorescent
labeled HA (F-HA) binding/uptake was high in non-adherent cells but dropped over
time as cells became increasingly adherent. Non-adherent cells displayed both CD44
and RHAMM but only function-blocking anti-RHAMM and not anti-CD44 antibodies
significantly reduced F-HA binding/uptake. Adherent cells, which also expressed CD44
and RHAMM, primarily utilized CD44 to bind to F-HA since anti-CD44 but not anti-
RHAMM antibodies blocked F-HA uptake. RHAMM overexpression in adherent 10T½
cells led to increased F-HA uptake but this increased binding remained CD44 dependent.
Further studies showed that RHAMM-transfection increased CD44 mRNA and protein
expression while blocking RHAMM function reduced expression. Collectively, these
results suggest that cellular microenvironments in which these receptors function as
HA binding proteins differ significantly, and that RHAMM plays at least two roles in F-
HA binding by acting as an HA receptor in non-attached cells and by regulating CD44
expression and display in attached cells. Our findings demonstrate adhesion-dependent
mechanisms governing HA binding/ uptake that may impact development of new
mesenchymal cell-based therapies.
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INTRODUCTION
Wound and tumor microenvironments are dynamic composites
of in-trafficking and resident cells within a scaffold of
remodeling or “provisional” extracellular matrix (Bissell and
Hines, 2011; Catalano et al., 2013; Mehner and Radisky, 2013;
Bhat and Bissell, 2014; Blonska et al., 2015; Chen et al.,
2015). Among the many non-immune cell types, mesenchymal
progenitor cells have emerged as critical players in wound
repair and diseased tissue (e.g., cancer) microenvironments
(Cuiffo and Karnoub, 2012; Vannucci, 2014; Kfoury and Scadden,
2015). Mesenchymal progenitor cells differentiate into activated
fibroblasts, myofibroblasts, adipocytes, endothelial, and other
cell types that are essential for normal wound repair and
are increasingly used as a cell therapy to improve wound
repair (Glenn and Whartenby, 2014; Hossain et al., 2014;
King et al., 2014; Petrof et al., 2014; Wang et al., 2014a;
Zahorec et al., 2015). Mesenchymal cells also contribute to
formation of cancer-associated fibroblasts (CAFs) present in the
tumor microenvironments that facilitate neoplastic progression
(Barcellos-de-Souza et al., 2013; Mehner and Radisky, 2013;
Cortez et al., 2014; De Wever et al., 2014; Xiong et al., 2015).
CAF transcriptomes resemble those of wounded or activated
fibroblasts, and both wound fibroblast and CAF signatures have
prognostic value in a number of cancers (Casey et al., 2009; Lim
et al., 2011; Tchou et al., 2012; Herrera et al., 2013; Mehner and
Radisky, 2013; Paulsson and Micke, 2014; Isella et al., 2015).
Part of the function of mesenchymal progenitor cells in wounds
and diseased tissues are the production and metabolism of key
extracellular matrix components.
The polysaccharide hyaluronan (HA) is an ECM molecules
produced by mesenchymal progenitor cells that performs key
functions in wounds and diseases such as cancer (Itano
et al., 2008; Veiseh and Turley, 2011; Nikitovic et al., 2013a;
Provenzano and Hingorani, 2013; Bourguignon et al., 2014;
Dicker et al., 2014; Kouvidi et al., 2014; Schmaus et al., 2014;
Tolg et al., 2014; Briggs et al., 2015; Finlayson, 2015; Misra
et al., 2015; Nagy et al., 2015). Like many ECM molecules HA is
fragmented in wound and tumor microenvironments as a result
of free radical and enzymatic (hyaluronidase) de-polymerizing
activity (Stern and Maibach, 2008; Heldin et al., 2013; Nikitovic
et al., 2013a,b; McAtee et al., 2014; Parsons, 2015). HA fragments
have different signaling properties than the native HA polymer
as a result of their selective binding to HA receptors. During
both wound repair and neoplastic progression, HA fragments
appear to be more active in promoting in-trafficking of immune
and stem cells than native HA (>500 kDa) (Jiang et al., 2011;
Petrey and de la Motte, 2014; Schaefer, 2014; Singleton, 2014;
Tolg et al., 2014; Ghosh et al., 2015). In wounds, both native
HA and HA fragments interact with mesenchymal progenitors
and contribute to their fate determination (Khaldoyanidi et al.,
2014; Kota et al., 2014; Kouvidi et al., 2014). HA is constitutively
elevated inmany cancers and its increased accumulation in either
the tumor or peri-tumor stroma is associated with poor outcome
in a number of malignancies in particular breast and prostate
cancers (Toole, 2004; Tammi et al., 2008; Heldin et al., 2013;
Khaldoyanidi et al., 2014; Kouvidi et al., 2014). Mesenchymal
progenitor cells are emerging as key regulators of HAmetabolism
during progression of these cancers (Astachov et al., 2011;
Caralla et al., 2012; Khaldoyanidi et al., 2014; Kouvidi et al.,
2014). However, the expression of HA receptors and/or their
respective roles in binding and uptake of this polysaccharide by
mesenchymal progenitor cells are not yet well characterized.
The current studies were designed to identify the key
HA receptors that mediate HA interaction and uptake by
mesenchymal progenitor cells. We utilize 10T½ cells as a
model of mesenchymal progenitor cells since these have
been shown to exhibit the capacity to differentiate into
adipocytes, chondrocytes, myofibroblasts, smooth muscle cells,
and endothelial cells (Salvatori et al., 1995; Artaza et al.,
2008; Kennard et al., 2008; Wang et al., 2010). We show
that these cells utilize two well characterized HA receptors
CD44 and RHAMM/HMMR for HA binding and uptake.
Importantly, receptor usage for HA internalization is cell
attachment dependent. Whereas adherent 10T½ cells use CD44
as an endocytic HA receptor, suspended and newly attached cells
utilize RHAMM/HMMR as the dominant HA receptor.
METHODS
Preparation of F-HA and G-HA Probes
Texas Red, Cy5.5, or gold was conjugated to HA (240 kDa, Hyal
pharmaceutical), and according to previously described methods
for use in adherent cells (Collis et al., 1998; Gouin and Winnik,
2001; Veiseh and Turley, 2011). For analysis of suspended
cells, Alexa fluor 647-HA probes were developed by conjugating
polydisperse 240 kDa Sodium Hyaluronate (1%, Lifecore) to
Alexa-fluor 647-hydrazide dye (120 kDa, Life Technologies).
Two-hundred µL of HA and 300µL dye (1 mg/mL) were
added to 1mL of conjugation buffer [20mM MES, 30% EtOH,
0.0028 g/mL 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide].
The mixture was set on a rocker at room temperature in the
dark overnight. The solution was then dialyzed against 1× PBS in
3mL slide-a-lyzer cassettes (10,000mWCO, Thermoscientific),
changing the dialysate every 24 h for 4 days. For transmission
electron microscopy (Maxwell et al., 2011), gold was linked to
HA (240 KDa, G-HA) using previously published protocols for
preparing gadolinium-HA (Gouin and Winnik, 2001).
Addition of HA-probes to Adherent Cells
Medium of 40% subconfluent cell cultures was changed to
serum-free low glucose DMEM (Gibco, BRL) containing 4µg/ml
transferrin (Gibco, BRL), 4µg/ml insulin (Gibco, BRL), and
10mM Hepes (Sigma). After overnight incubation, cells were
exposed to 100µg/ml Texas red, Cy5.5, and or gold-HA for
10min in defined (low glucose DMEM) medium containing
insulin and transferrin. 100 ug/ml FITC-dextran (10 KDa,
Molecular Probes) was added at the same time to provide a
process for standardizing fluorescent intensity and as a measure
of constitutive uptake. For confocal microscopy, cells were grown
on coverslips and after F-HA uptake were rinsed twice in cold
5X PBS and fixed in 2% freshly prepared paraformaldehyde +
1% cetylpyridinium chloride as described. Coverslips were then
Frontiers in Cell and Developmental Biology | www.frontiersin.org 2 October 2015 | Volume 3 | Article 63
Veiseh et al. RHAMM regulates CD44 in progenitors
washed in 1 × PBS and mounted using fluorescent mounting
medium (DAKO).
Tissue Fixation for Transmission Electron
Microscopy
For transmission electron microscopy, cells were fixed with 2.5%
glutaraldehyde, 1.5% paraformaldehyde, and 2.5% DMSO in
cacodylate buffer, then post fixed in osmium tetroxide (Veiseh
et al., 2014).
HA Fragment Size Analyses
For HA fragment uptake analyses, Texas red end labeled HA
fragments (HA4, HA8, HA12, HA26, and HA30, kind gift of M.
and R. Tammi, U. Kuopio, Finland) were added to cells, which
were fixed and processed as above. HA fragments were generated
by digestion with hyaluronidase and purified by chromatography
as described (Siiskonen et al., 2013).
Quantification of Binding and Uptake of
F-HA in Attached Cells
Cells were examined with a Zeiss Axiophot 100 confocal
microscope and z-axis images taken through the middle of cells
were analyzed for Texas red or Alexa647-HA, collectively termed
F-HA, uptake. UTHSCA image Tool (version 1.28, University of
Texas Health Sciences Center in San Antonio) was used and zero
thresholding of equal central sections taken from the perinuclear
areas were implemented as represented in Figure 2A. Staining
of cells with different cell thicknesses was standardized using a
ratio of Texas red-HA:FITC-dextran fluorescence. Background
staining, which included autofluorescence and fluorescence
following uptake of Streptomyces hyaluronidase-digested Texas
red HA (digested to completion), was subtracted from the raw
data.
Flow Cytometry of Suspended Cells
10T½ (parental) and RHAMM-transfected 10T½ cells
(RHAMM-10T½) were brought to 50% confluence in low-
glucose DMEM media (10% FBS) and released from the culture
surface using 1× non-enzymatic dissociation solution (Sigma-
Aldrich). Cells were pelleted then re-suspended at 2.5 × 105
cells per 100µL. For non-blocking conditions, cells were then
incubated with 1:20 monoclonal mouse anti-RHAMM (6B7B7)
for 30min on ice. Cells were spun and washed twice with 1mL
1× sterile PBS. They were then re-suspended in 1mL PBS
and incubated with Rat anti-mouse Alexa fluor 488 (1:2000)
secondary antibody, together with Rabbit anti-mouse CD44-RPE
conjugate (1:1000) (Clone IM7.8.1, Life Technologies) and
Alex-fluor 647-HA (133µg/mL) for 30min. Cells were then
washed and spun three times with 1mL 1× sterile PBS for flow
cytometry analysis.
Cell fluorescence was detected using a FACSCalibur II flow
cytometry machine and data were acquired using the Cellquest™
Pro analysis program (BD Biosciences). Forward Scatter and side
scatter light was collected through a 488/10 filter using the blue
(488 nm) laser, with side scatter collected at a 90◦ angle from the
original light path. RHAMM-bound Alexa fluor 488 and CD44-
PE fluorophores were excited using the 488 nm blue laser, with
the excitation wavelengths being detected by the FL1 (530-30)
and FL2 (585/42) light filters, respectively. F-HA was excited by
the 635 nm red diode laser, and detected by the FL4 (661/16)
light filter. The fluorescence voltage levels were adjusted using
the unstained and non-immune IgG control cells, moving the
events to the bottom left corner of the dot plot. Using single- and
double-stained controls, each fluorescent marker was adjusted by
compensation to its appropriate location (not appearing in an
improper filter). Twenty thousand gated events were acquired
per sample for data analysis. Flow data was then analyzed using
Flowjo V10 (Treestar Inc.).
Blocking HA Receptors and Inhibiting HA
Production in Suspended Cells
For assessing the consequences of blocking HA receptors on F-
HA binding and CD44 display, suspended cells were prepared
as described above then exposed to blocking antibodies prior
to F-HA or CD44 display analyses for 1 h in cell culture
medium 37◦C. Cells were then prepared for flow cytometry by
incubation with rabbit anti-mouse CD44-RPE antibody (Life
technologies) or F-HA as in five above. The CD44 function
blocking antibody (KM201) has previously been shown to reduce
HA:CD44 interactions (Culty et al., 1990) and the RHAMM
function blocking antibody (exon 8 rabbit polyclonal antibody)
reduced migration of RHAMM-rescued but not RHAMM–/–
cells (Tolg et al., 2006).
To assess CD44 membrane display when endogenous HA
production has been blocked, under (4-MU) treatment, adherent
RHAMM-transfected 10T½ cells were incubated with 1mM
4-Methylumbelliferone (4-MU) for 4 h at 37◦C (Rilla et al.,
2004). Cells were then prepared for flow cytometry as previously
described above and stained using the Rabbit anti-mouse CD44-
RPE antibody (Life Technologies).
RHAMM Transfection of 10T½Fibroblasts
10T½ fibroblasts were stably transfected with an N-terminal
truncated RHAMM cDNA(1163aa)/hygromysin construct
driven by a ß-actin promoter (Hall et al., 1995). This RHAMM
cDNA encodes an isoform commonly expressed in cancer cell
lines (Savani et al., 1995; Tolg et al., 2006; Hamilton et al.,
2007) and following tissue wounding. Stably transfected cells
were selected in G418 and cloned (Hall et al., 1995). The clone
(designated RHAMM-10T½) was used in the present study.
Western Blots and HA-sepharose
Pull-down Assays
Western blot analysis of RHAMM expression was performed
as previously described (Hamilton et al., 2007) using polyclonal
anti-peptide antibodies screened for specificity by RHAMM−/−
and RHAMM+/+ fibroblast lysates. CD44 western blot analysis
on 10T½ fibroblasts as well as RHAMM-transfected 10T½ cells
was performed as previously described (Tolg et al., 2006), with
the exception of using primary anti-CD44 antibodies (AF6127,
R&D systems) at 1µg/mL overnight. Secondary antibodies were
incubated for 1 h at room temperature (Bethyl Laboratories).
Flow cytometry was performed using anti-CD44 antibodies
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(IM7, Pharmingen). HA-sepharose pulldowns were performed as
described previously (Tolg et al., 2012). For antibody blocking
experiments, antibody was added to cultures for 30min followed
by Texas red-HA as described above.
Microarray Analysis and QPCR
Microarray analysis and QPCR were performed as previously
described (Tolg et al., 2012). In brief, subconfluent 10T½ and
RHAMM-transfected 10T½ cells were cultured overnight in
serum free defined medium (DMEM, 4µg/mL insulin, 8µg/mL
transferrin). Total RNA from three biological replicates was
isolated using TRIzol Reagent (Invitrogen) and purified using
the QIAGEN RNAeasy kit (Qiagen, Valencia, CA) following
the manufacturer’s instructions. RNA quality was assessed using
Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara,
CA) and the RNA 6000 Nano kit (Caliper Life Sciences,
Hopkinton, MA). Double-stranded cDNA was synthesized using
SuperScript II (Invitrogen) and oligo primers. Labeled cRNA
was prepared using the BioArray High-Yield RNA Transcript
Labeling kit (Enzo Biochem, New York, NY) and Mouse
Genome 430 2.0 GeneChips (Affymetrix, Santa Clara, CA)
were hybridized with 10µg labeled cRNA as described in
Affymetrix GeneChip Technical Analysis manual (Affymetrix,
Santa Clara, CA). Biotinylated cRNA was detected with
streptavidin-phycoerythrin (S-P) using a GeneChip Fluidics
Station 450. GeneChips were scanned with the Affymetrix
GeneChip Scanner 3000 (Affymetrix). Signal Intensities for all
genes were generated using GCOS1.3 (Affymetrix) using default
values for the Statistical Expression algorithm parameters and
a target signal of 150 for probe sets and a normalization value
of 1. Data were then transformed (<0.01 set to 0.01) and
normalized per chip to the 50th percentile and per gene to
controls. To determine the effect of RHAMMon gene expression,
RHAMM-transfected 10T½cells were compared to10T½cells.
GeneSpring GX 7.3.1. (Agilent Technologies) was used to
identify fold changes in gene expression between the two cell
lines by applying a t-test with Bonferroni multiple testing
correction with a significance cut-off of 0.05. Genes with a
two-fold or higher difference in expression were considered for
further analysis. All gene chips were processed at the London
Regional Genomics Centre (Robarts Research Institute, London,
ON, Canada). Signaling pathways were identified by Ingenuity
Pathway Analysis (Ingenuity Systems, Redwood City, CA).
Cytoskeleton Disruption with
Cytochalasin B
Cytochalasin B (10µM, Sigma) was added to adherent RHAMM-
transfected fibroblasts for 30min prior to the addition of Texas-
red HA.
Statistical Analyses
Statistical significance of experiments comparing means of
fluorescence intensity (F-HA uptake) was calculated using 2-
tailed 2 sample t-tests. The means compared were: unblocked
and short HA fragment-blocked cells (Figure 2C) 10T½cells
and HA-mutant cells (Figure 7C), 10T½MEFs, and RHAMM-
transfected 10T½cells (Figures 3A,C,D, 4C, 5A), and cells
blocked with an IgG or anti-RHAMM antibody (Figure 5A).
Minimum significance was set at p < 0.05.
RESULTS
Suspended and Attached 10T½ Cells Bind
and Internalize F-HA and G-HA
To begin to characterize 10T½ mesenchymal progenitors for
their ability to metabolize HA, cells were exposed to Alexa-647-
or Texas Red-HA (collectively termed F-HA) (Figures 1A–C),
and Gold-HA (G-HA) probes (Figure 1D). Bound probes
were detected using flow cytometry (Figure 1A), confocal (F-
HA, Figure 1B) or transmission electron microscopy (G-HA,
Figure 1D). Flow cytometry shows that suspended 10T½ cells
bind F-HA in a heterogeneous manner as indicated by tailing
of the binding profile (Figure 1A, arrow). Confocal analyses
(e.g., Figure 1B) of adherent 10T½ cells confirm that the F-
HA binds to cell surfaces (e.g., arrows, Figure 1B) and is
internalized in cytoplasmic vesicles that are associated with
the cytoskeleton (Figure 1B, arrowheads). The importance of
the actin cytoskeleton to internalization of F-HA is further
demonstrated by the ability of cytocholasin B, which disrupts
actin filament assembly, to inhibit F-HA uptake (Figure 1C). F-
HA also accumulates in the perinuclear area and is apparent in
the nuclei of adherent cells (Figures 1B, 2A, heat map circle).
This vesicular uptake pattern is confirmed by TEM using gold
labeled HA (G-HA) and unlabeled gold as a negative control
(Figure 1D). Analysis of cell sections confirm that G-HA is
present in a pericellular coat (Siiskonen et al., 2015) (Figure 1D,
black arrows) and in cytoplasmic vesicles (Figure 1D, inset, white
arrows) that are present in cell processes and in the perinuclear
area. By contrast, uptake of FITC-dextran, used as a marker
for HA receptor independent uptake (pinocytosis), shows low
to no accumulation in the perinuclear/nuclear regions (compare
Figures 2A,B). The presence of labeled HA within vesicles is
consistent with an HA receptor mediated endocytic mechanism
(Thankamony and Knudson, 2006).
F-HA Probe Uptake is Polymer Size and
Cell Attachment Dependent
The binding of HA to its receptors is typically size dependent
while non-specific uptake (e.g., pinocytosis) is not (Mills and
Finlay, 1994; Ma et al., 2013). We therefore first evaluated the
binding and uptake of sized HA oligosaccharides in adherent
10T½ cells and compared results with uptake of FITC-dextran,
used as a marker for non-HA receptor mediated internalization
(Figures 2A–C). Since RHAMM and CD44 are expressed on
mesenchymal progenitor cells (Shigeishi et al., 2013), HA
oligosaccharides ranging from 8 to 30 saccharides, which are
known to bind to these receptors (Nikitovic et al., 2013a), were
analyzed for uptake (Figure 2C). Notably, CD44 binds to a
minimum of six dissacharides but is only clustered by larger
polymers, which is required for endocytosis (Yang et al., 2012).
10T½ cells internalize F-HA8 to F-HA12 at a level slightly above
the FITC-dextran background (Figure 2C, dotted line) but F-
HA26−30 are internalized to a significantly greater extent than
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FIGURE 1 | F-HA binds to and internalized by detached and adherent 10T½ cells. (A) Flow cytometry analysis shows heterogeneous binding (high binding
notated by black arrow) and uptake of F-HA by non-adherent parental 10T½ cells (red). Cells that were not exposed to F-HA (e.g., unstained cells) are shown as a
negative control (blue). (B) Confocal micrograph of F-HA internalized by adherent 10T½ cells shows the probe is located at the cell surface (arrows), as well as inside
the cells where it accumulates in the perinuclear and nuclear areas (arrowheads). (C) F-HA uptake in adherent RHAMM-10T½ cells is blocked by disruption of the
actin cytoskeleton using cytochalasin B confirming a role for the cytoskeleton in F-HA uptake by adherent cells. (D) Transmission electron micrograph confirms that
G-HA accumulates at the extracellular face or the glycocalyx of cells (arrows) and is internalized in vesicles (inset), which are abundant in cell processes, and in the
peri-nuclear areas, and are associated with the cytoskeleton (black arrow, inset) consistent with a role for endocytic processes in internalization of the HA probe.
these two smaller HA fragments. These results show that F-HA
internalization is influenced by F-HA size in a manner that is
consistent with a role for HA receptors in the internalization
process.
Here, we show that F-HA uptake is also affected by the
adhesion status of 10T½ cells. Uptake is highest in 10T½ cells
2 h after plating when cells are initially attaching, but drops
significantly between 12 and 24 h after plating (Figure 3A, black
bars), when cells are firmly adherent as judged by a flattened
morphology. Constitutive RHAMM expression is rare in most
tissues or confluent cultures (Savani et al., 1995; Tolg et al.,
2006) and has been reported to drop with time following cell
plating (Zhang et al., 1998). Our results confirm this transient
expression in 10T½ cells between 2 and 24 h post-subculture
(Figure 3B). A RHAMM cDNA was therefore transfected into
10T½ cells to sustain expression of this protein and to determine
if this forced expression stabilizes high F-HA uptake after cell
subculture. A more than two-fold increase in the expression of
RHAMM is confirmed with mRNAmicroarray (Table 1), Q-PCR
(Table 1 and Figure 3C) and western blot (Figure 3D) assays,
measuring expression in adherent cells 24 h after subculture.
RHAMMoverexpression stabilizes F-HA binding/internalization
in 10T½ cells over time after subculture so that even at 24 h levels
remain high (Figure 3A, gray bars). Uptake of increasing F-HA
concentrations by parental and RHAMM-10T½ cells at 24 h
after subculture was next quantified to determine if increased
F-HA uptake in RHAMM-10T½ results from increased HA
receptor display. For these experiments, F-HA uptake was
standardized against that of FITC-dextran internalization to
account for the role of pinocytosis in probe uptake, which is
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FIGURE 2 | F-HA oligosaccharides are internalized by 10T½ cells. (A)
Confocal micrograph showing the perinuclear and nuclear area used for
quantification of texas red-HA in adherent cells (left image); middle micrograph
is a phase contrast image of the cell and right image is a heat map of the
fluorescent texas red-HA staining. (B) Confocal micrograph of adherent 10T½
cells shows the fluorescent uptake of FITC-dextran, which is not HA receptor
mediated. (C) Internalization of sized HA fragments end-labeled with Texas
red, was measured against a background of FITC-dextran uptake. Results
show that HA polymers of 8–12 saccharides are internalized slightly above the
FITC-dextran background, but internalization is significantly increased when
polymer sizes reach to 26 or more saccharides. Confocal micrographs are
representative images (Bar = 10µm). Values are the mean and SEM of n = 40
cells. Asterisks indicate statistical significance (p < 0.05).
not HA receptor mediated. F-HA uptake by the parental 10T½
cells reaches saturation between 1.0 and 1.5mg/ml F-HA but
continues to increase in RHAMM-transfected cells to 3.5mg/ml
(Figure 3E). These results suggest that sustained expression
of RHAMM increases F-HA uptake through increasing HA
receptor expression/display, which is required for F-HA
internalization.
CD44 Mediates F-HA Uptake in Adherent
10T½ Cells
Since RHAMM-10T½ cells constitutively express elevated
RHAMM, the role of this HA receptor in F-HA internalization
by adherent cells was examined. The function blocking anti-
RHAMM antibody significantly reduces F-HA uptake by
RHAMM-10T½ cells but the effect is slight and does not account
for the majority of uptake (Figure 4A). To verify that RHAMM-
10T½ cells express HA binding CD44 proteins, pull-down assays
using HA-Sepharose were performed (Figure 4B). Results show
that CD44 protein is strongly expressed in RHAMM-10T½
cells and that the standard and variant forms of CD44 bind to
HA-sepharose. A smaller CD44 protein form (60 kDa), which
is likely to be the soluble form of this HA receptor, also binds
to HA-Sepharose. The effect of blocking CD44:HA interactions
on F-HA uptake by RHAMM-10T½ cells was therefore next
examined using a function blocking CD44 antibody (Figure 4C).
Results show that this antibody blocked the majority of F-HA
uptake in adherent parental and RHAMM-10T½ cells suggesting
that CD44 is the primary endocytic HA receptor in both 10T½
cell types. Collectively, these results also predict that sustained
RHAMM expression may be affecting expression and/or display
of CD44.
RHAMM Transfection Regulates CD44
Expression in 10T½ Cells
To assess if RHAMM transfection increases transcription of
CD44, RHAMM-10T½ vs. parental 10T½ mRNA microarray
analyses were performed. Results confirm that RHAMM
expression is significantly increased, as expected and show
that CD44 mRNA expression is also increased (Table 1). This
effect is selective for CD44 since changes in expression levels
of other characterized HA receptors are either not detected
or are decreased (STAB2 mRNA levels are decreased). Q-
PCR confirms the increase in CD44 mRNA detected by
microarray analyses (Table 1) and western blots also demonstrate
a similar increase in CD44 protein levels (Figure 5A). These
results suggest that RHAMM transfection either promotes CD44
transcription or regulates the stability of the CD44 mRNA.
A potential transcriptional effect could be a direct result of
RHAMM since it has recently been shown to participate in
gene transcription (Meier et al., 2014). Alternatively it could
be an indirect effect resulting from its ability to promote
signaling pathways that control CD44 expression or mRNA
stability. For example, RHAMM could alter signaling through
growth factors such as PDGF (Nikitovic et al., 2013a) or
ligands such as HA (Tolg et al., 2014). To begin to assess
this, the signaling functions of cell surface RHAMM were
blocked in RHAMM-10T½ cells using the function-blocking
antibody. As well, HA production was inhibited by 4MU
and the consequences of these two treatments to CD44
expression was quantified using flow cytometry (Figures 5B,C).
The RHAMM antibody reduces CD44 display by approximately
10-fold although a subpopulation of CD44 is unaffected, as
indicated by an increased peak width around 103 signal
(Figure 5B). Inhibiting HA production by 4MU also reduces
CD44 display (Figure 5C). Collectively these results predict
that RHAMM signaling, possibly through HA, affects CD44
expression/display of RHAMM-10T½ cells indirectly controlling
CD44 mediated HA uptake (Tolg et al., 2012; Bourguignon et al.,
2014).
RHAMM Mediates F-HA Binding in
Suspended RHAMM-10T½ Cells
The ability of stem cells to traffic to sites of tissue injury via
the vasculature requires their survival as non-adherent cells.
The ability to survive as suspended cells has been linked to
HA:cell interactions amongst other microenvironmental factors
that influence susceptibility to apoptosis (Zhang et al., 2015).
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FIGURE 3 | RHAMM overexpression in 10T½ cells increases F-HA uptake. (A) F-HA uptake is highest in newly plated 10T½ cells but drops over time as cells
become firmly attached and form an organized actin cytoskeleton (e.g., 24 h time point). In contrast, F-HA uptake in RHAMM-10T½ cells remains high between 2 and
24 h. (B)Western blot shows RHAMM protein expressed by parental 10T½ cells decreases with time after subculture. (C) Q-PCR analyses confirm that RHAMMmRNA
expression is significantly higher in RHAMM-10T½ cells than in the parental counterpart at 24 h after subculture (asterisk indicates statistical significance, p < 0.05). (D)
Western blot shows that RHAMM protein is also expressed at higher levels in RHAMM-10T½ cells vs. parental cells at 24 h after subculture. (E) Analysis of F-HA binding
to RHAMM-10T½ and parental cells with increasing F-HA concentration. Graphs shows that RHAMM-10T½ cells bind more F-HA than parental counterparts suggesting
RHAMM transfection increases display of HA receptors. Values are the mean and SEM of n = 50 cells. Asterisks indicate statistical significance (p < 0.05).
TABLE 1 | Microarray analyses of HA receptor expression changes in
RHAMM-transfected vs. parental cells.
Gene Fold change P-value
Microarray Q-PCR Microarray Q-PCR
RHAMM/HMMR 2.37* 2.95* 2.369E-08 0.05
CD44 2.29* 2.69* 2.93E-07 0.05
STAB2 1.75 ND 1.70E-05 ND
LYVE1 No change
STAB1 No change
KIAA1199 (CEMIP) No change
C1QBP (HABP1) No change
RHAMM transfection sustains RHAMM mRNA expression and also increases mRNA
expression of CD44 but not other characterized HA receptors. (*p < 0.05).
ND means Not Determined.
We therefore analyzed the mechanisms by which suspended
RHAMM-10T½ cells bind to F-HA. Multiplexed flow cytometry
shows that suspended RHAMM-10T½ cells display both
CD44 and RHAMM although CD44 is much more abundant
than RHAMM (Figure 6A). F-HA binding to these cells is
heterogeneous (Figures 6B, 7A,B). Subpopulations that bind
the highest levels of F-HA (HAhigh) display higher levels of
RHAMM than subpopulations of cells that bind low or no F-HA
(HAlow) (Figure 6B). In contrast, CD44 display is abundant on
both HAhigh and HAlow subpopulations. Function blocking anti-
CD44 and RHAMM antibodies were used to assess the direct
vs. indirect roles of these two HA receptors in binding F-HA
to suspended RHAMM-10T½ cells. Unexpectedly, anti-CD44
antibodies do not block F-HA binding to suspended RHAMM-
10T½ cells, when compared to the effect of non-immune IgG
(Figure 7A). In contrast the anti-RHAMM antibody strongly
block F-HA binding in these assays (Figure 7B). However,
binding is not completely ablated by blocking RHAMM function,
indicating that other receptors are involved in F-HA interactions
with the suspended cells. These results prompted us to assess
the contribution of RHAMM in F-HA uptake of parental
10T½ cells that are in the process of attaching, a time after
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FIGURE 4 | CD44 binds to F-HA, and the uptake in adherent RHAMM transfected cells is CD44-dependent. (A) F-HA probe uptake in adherent
RHAMM-10T½ cells is significantly blocked. Values are the mean and SEM of n = 50 cells and asterisks indicate statistical significance (p < 0.05) by function blocking
anti-RHAMM antibodies but the effect is slight. (B) 240 kDa HA-sepharose pulls down CD44 standard, variant and soluble forms from 10T½ cell lysates, but in
contrast, and as expected, HA4 does not. (C) Anti-CD44 antibodies strongly block F-HA uptake in both parental and RHAMM-10T½ cells indicating that this receptor
is primarily responsible for the RHAMM-mediated increase in F-HA internalization, and is the major endocytic HA receptor in adherent cells. Values are the mean and
SEM of n = 50 cells. Asterisks indicate statistical significance (p < 0.00001).
subculture when RHAMM expression and F-HA binding/uptake
is high (Figure 7C). For these experiments, parental 10T½ cells
were transfected with a dominant negative acting RHAMM
HA binding mutant that reduces HA binding to this protein.
Expression of this mutant ablates the elevated F-HA uptake of
cells that are attaching to the growth substratum (Figure 7C,
2–12 h) but not adherent cells (Figure 7C, 24 h). Therefore,
the mechanisms used for HA binding/update by suspended
or newly attaching are different from adherent 10T½ cells.
Collectively, these results suggest that both CD44 and RHAMM
canmediate HA binding and uptake via CD44 uptake requires an
organized actin cytoskeleton (e.g., Figure 1D) typically found in
adherent cells while HA binding via RHAMM predominates in
non-adherent cells.
DISCUSSION
It has been increasingly shown that adherence, fate, and function
of mesenchymal stem or progenitor cells are influenced by HA,
however less is known about how these cells metabolize HA.
Mesenchymal progenitor cells are undifferentiated multi-potent
stromal cells originally identified in the bone marrow stroma
but which have since been detected in many additional tissues
(Hossain et al., 2014; Naderi-Meshkin et al., 2015). These cells
traffic to sites of injury where they differentiate into adipocytes,
osteoblasts, chondrocytes and fibroblasts/myofibroblasts thus
providing a mechanism for self-renewal in the repair of
mesenchymal tissues (Ding et al., 2015; Wong et al., 2015). They
additionally play key immunomodulatory and nurturing/support
Frontiers in Cell and Developmental Biology | www.frontiersin.org 8 October 2015 | Volume 3 | Article 63
Veiseh et al. RHAMM regulates CD44 in progenitors
FIGURE 5 | RHAMM affects CD44 expression. (A) Western blot analysis of adherent RHAMM-10T½ cell lysates reveals an approximately two-fold increase in the
expression of CD44s protein compared to the parental cells (replicated twice). (B) Function blocking anti-RHAMM antibody reduces the display of CD44 on
RHAMM-10T½ cells. (C) Reduction of CD44 display is observed when HA production by these cells is inhibited with 4MU.
roles in stem cell niches required for tissue homeostasis (Glenn
and Whartenby, 2014; Kfoury and Scadden, 2015). The homing
andmultipotential properties of these cells has stimulated interest
in a number of clinical applications including tissue engineering
for regenerative medicine and delivery tools to treat cancer and
other diseases (Ghobadi et al., 2015; Park et al., 2015).
Production and turnover of ECM components (includingHA)
within repairing and diseased tissues is a key process. Both
resident and trafficking msenchymal progenitor cells produce
and respond to HA, thus contribute to directing the homing,
growth and differentiation of mesenchymal progenitor cells into
a number of lineages (Avigdor et al., 2004; Herrera et al., 2007;
Astachov et al., 2011; Kishi et al., 2012; Dicker et al., 2014).
This differentiation capability of mesenchymal progenitor cells
is increasingly utilized in tissue engineering designs (Astachov
et al., 2011; Prestwich et al., 2012; Khaldoyanidi et al., 2014).
Our major findings are that the 10T½ mesenchymal cell model
utilizes both CD44 and RHAMM to bind and internalize HA.
Importantly, the cellular contexts in which these receptors
function as HA binding proteins differ significantly. CD44 is the
primary HA endocytic receptor in adherent mesenchymal cells,
however this function requires an organized cytoskeleton typical
of adherent cells. By contrast, RHAMM performs a number of
functions in HA binding/internalization by these mesenchymal
progenitor cells because it both regulates expression of CD44
when cells are adherent and acts as a major HA binding receptor,
when 10T½ cells are suspended or newly attached.
Previous reports have extensively documented that CD44
interacts both directly and indirectly with the actin cytoskeleton
in adherent cells. Several reports have noted that CD44-mediated
HA binding requires an association with phosphorylated
ERM (ezrin, radixin, and moesin) proteins and the actin
cytoskeleton (Bourguignon et al., 2013). Consistent with our
present observations, a previous study showed that disruption
of polymerized actin inhibits CD44 clustering and abolishes HA
binding in myeloid cells (Brown et al., 2005). Flow cytometry
requires the use of suspended cells and thus these predict that HA
dependent non-adherent trafficking of mesenchymal cells likely
depends more on cell surface RHAMM: HA interactions than
CD44: HA interactions.
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FIGURE 6 | CD44 and RHAMM are displayed on suspended RHAMM-10T½ cells. (A) Single channel flow cytometry analysis of CD44 and RHAMM levels
shows that CD44 levels are higher than RHAMM and that channel bleed through does not occur. (B) Multiplexed flow analysis of HA receptor display in
RHAMM-10T½ cell subpopulations that bind low (blue, HAlow bottom 5% of events) or high (red, HAhigh top 5% of events) amounts of F-HA probe show that CD44 is
abundant in both subpopulations. In contrast, the highest RHAMM display is unique to the HAhigh subpopulation.
RHAMM is a multifunctional cytoplasmic protein that, like
many unconventionally exported cytoplasmic proteins, appears
on the cell surface under very specific conditions of cell stress
(Maxwell et al., 2008; Radisky et al., 2009). Inside the cell it
binds to such proteins as tubulin, ERK1 and TPX2 that impact
mitotic spindle orientation and integrity (Maxwell et al., 2008;
Kouvidi et al., 2014; Tolg et al., 2014). Since RHAMM is not an
integral membrane protein, it affects activation of HA stimulated
signaling pathways by functioning as a co-receptor for integral
membrane proteins such as CD44 and/or growth factor receptors
(Shigeishi et al., 2014; Tolg et al., 2014). Our data suggest
that cell surface RHAMM may not partner with CD44 in the
binding and internalization of HA by the non-adherent cells.
Instead, RHAMM may partner with other integral membrane
receptors such as growth factor receptors (PDGFR, EGFR, or
RON) (Nikitovic et al., 2013a; Tolg et al., 2014) or other HA
receptors (Forteza et al., 2012; Heldin et al., 2013).
Intracellular RHAMM traffics to the cell nucleus and more
recent studies show that it binds to and participates in E2F1
transcriptional functions including expression of fibronectin,
providing a context in which intracellular RHAMM regulates
gene transcription (Meier et al., 2014). We and others (Gouëffic
et al., 2006; Hatano et al., 2011; Foley et al., 2012; Park et al.,
2012; Tolg et al., 2014; Wang et al., 2014b) have shown that
RHAMM controls activation kinetics and subcellular localization
of ERK1,2, MAP kinases that have been reported to promote
CD44 expression (Recio and Merlino, 2003; Judd et al., 2012).
Cell surface RHAMM can activate ERK1,2 via binding to
HA while intracellular RHAMM traffics into the cell nucleus,
where it could potentially participate in transcription directly.
Defining whether or not signaling that increases CD44 expression
originates from cell surface RHAMM-mediated activation of
ERK1,2 and/or from direct intracellular RHAMM transcriptional
function requires further study.
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FIGURE 7 | F-HA probe binding to suspended RHAMM-10T½ cells is reduced by anti-RHAMM but not anti-CD44 antibodies. (A,B) When compared to
isotype matched non-immune IgG, function blocking anti-CD44 antibodies do not reduce binding of F-HA probe to suspended 10T½ cells (A) whereas anti-RHAMM
antibody does (B). (B, C) Expression of a dominant negative HA mutant that blocks HA binding to RHAMM significantly reduces F-HA internalization in attaching
(2–12 h post subculture) but not firmly adherent 10T½ cells (24 h post subculture). Values are the mean and SEM of n = 50 cells. Asterisks indicate statistical
significance p < 0.05.
Our findings are relevant to both tissue repair and to such
diseases as cancer (Schäfer and Werner, 2008; Astachov et al.,
2011; Kishi et al., 2012; Tolg et al., 2014; Neuman et al., 2015).
For example, HA and its pattern of fragmentation during wound
repair contributes to the damage-associated molecular patterns
(DAMPs) that trigger an inflammatory response (Schaefer, 2014).
Blocking HA metabolism by deleting CD44 results in increased
tissue HA accumulation in the lung following bleomycin-induced
injury, leading to unremitting inflammation and ultimately tissue
destruction (Jiang et al., 2011). As well, initiation and progression
of cancer are profoundly affected by HA accumulation and
metabolism, which is contributed to by mesenchymal cells
within the peri-tumor stroma (Itano and Kimata, 2008;
Kouvidi et al., 2014; Zhao et al., 2015). For example,
elevated accumulation of HA in stroma is a poor prognostic
factor in a number of cancers including oral squamous cell
carcinoma, breast and prostate cancers (Tolg et al., 2014). CAFs,
which can differentiate from mesenchymal progenitor cells,
are heterogeneous, and one recently identified subpopulation
produces high levels of HA that promotes motility and
invasion of tumor cells. In addition, tumor microenvironments
favor production of free radicals, which fragment HA into
smaller polymers [29] thus replicating an environment that
resembles that of wound. There is now increasing evidence
that such microenvironments fuel tumor aggression. The HA
binding functions of receptors expressed by stromal cells is
therefore an important part of creating a pro-tumorigenic
microenvironment.
We have shown previously that breast tumor cells are
heterogeneous in their ability to bind to F-HA probes (Veiseh
et al., 2014). Cell sorting based upon levels of F-HA binding
show that this differential binding is associated with distinct
phenotypic differences in tumor cells. Those that bind low
levels of F-HA are poorly invasive but proliferate while those
binding high levels of HA are highly invasive but proliferate
slowly. Mesenchymal progenitor cells used in the present study
were also heterogeneous in their ability to bind to F-HA, and
this property may likewise be associated with differences in
progenitor phenotypes (Caralla et al., 2012). At the least, F-
HA binding may aid in enriching mesenchymal stem cells for
therapeutic use particularly since isolation of these progenitors
has been hampered by lack of specific surface markers. For
example, mesenchymal stem cells in bone marrow aspirates can
be separated from myeloid precursor cells based upon their
relative ability to bind HA (Caralla et al., 2012).
In summary, here we have identified the HA receptors
required for HA binding and internalization by a mesenchymal
progenitor cell line. We show that depending upon the
attachment status of these cells, different HA receptors dominate
in carrying this function. Since mesenchymal progenitor cells
traffic to sites of tissue injury which requires changes in
their attachment status, and since HA metabolism affects
many processes during wound repair and disease (e.g., cancer
progression), our results may have clinical relevance for
development of new mesenchymal-based therapies.
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